 This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan administered with an investigational pen with daily Norditropin FlexPro somatropin delivered within a prefilled pen for 26 weeks in previously human growth hormone hGH treated adults with growth hormone deficiency. 